Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle

Warren V. Kalina, Amelia R. Woolums, Roy D. Berghaus, Laurel J Gershwin

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Safe RSV vaccine development has challenged the medical community since a formalin-killed RSV vaccine caused disease exacerbation in the 1960s. Disease was replicated using the bovine RSV system in one of two studies. The studies differed in viral protein dose and length of time between vaccination and infection. Disease exacerbation occurred in study 2 (previously reported). We hypothesized that low protein concentration in study 2's vaccine stimulated a TH2/IgE response that enhanced disease. BRSV-specific IgG1, IgG2, and IgE were measured by ELISA/Western blot from vaccinated/infected, vaccinated/mock infected, mock vaccinated/infected calves in both studies. Results revealed that study 2 calves produced more IgE, particularly to the nucleoprotein (N); IgE among study 2 calves correlated with high clinical scores. In contrast, study 1 calves showed stronger IgG responses to viral proteins.

Original languageEnglish (US)
Pages (from-to)1465-1474
Number of pages10
JournalVaccine
Volume22
Issue number11-12
DOIs
StatePublished - Mar 29 2004

Fingerprint

Respiratory Syncytial Virus Vaccines
formalin
Immunoglobulin E
Formaldehyde
immune response
calves
vaccines
Immunoglobulin G
viral proteins
cattle
Viral Proteins
Disease Progression
Inactivated Vaccines
nucleoproteins
Nucleoproteins
inactivated vaccines
vaccine development
Vaccination
Western blotting
Vaccines

Keywords

  • Bovine
  • Formalin-inactivated vaccine
  • IgE
  • RSV

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. / Kalina, Warren V.; Woolums, Amelia R.; Berghaus, Roy D.; Gershwin, Laurel J.

In: Vaccine, Vol. 22, No. 11-12, 29.03.2004, p. 1465-1474.

Research output: Contribution to journalArticle

Kalina, Warren V. ; Woolums, Amelia R. ; Berghaus, Roy D. ; Gershwin, Laurel J. / Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. In: Vaccine. 2004 ; Vol. 22, No. 11-12. pp. 1465-1474.
@article{8d50780f85d542a5b84750ca22a2cbee,
title = "Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle",
abstract = "Safe RSV vaccine development has challenged the medical community since a formalin-killed RSV vaccine caused disease exacerbation in the 1960s. Disease was replicated using the bovine RSV system in one of two studies. The studies differed in viral protein dose and length of time between vaccination and infection. Disease exacerbation occurred in study 2 (previously reported). We hypothesized that low protein concentration in study 2's vaccine stimulated a TH2/IgE response that enhanced disease. BRSV-specific IgG1, IgG2, and IgE were measured by ELISA/Western blot from vaccinated/infected, vaccinated/mock infected, mock vaccinated/infected calves in both studies. Results revealed that study 2 calves produced more IgE, particularly to the nucleoprotein (N); IgE among study 2 calves correlated with high clinical scores. In contrast, study 1 calves showed stronger IgG responses to viral proteins.",
keywords = "Bovine, Formalin-inactivated vaccine, IgE, RSV",
author = "Kalina, {Warren V.} and Woolums, {Amelia R.} and Berghaus, {Roy D.} and Gershwin, {Laurel J}",
year = "2004",
month = "3",
day = "29",
doi = "10.1016/j.vaccine.2003.10.024",
language = "English (US)",
volume = "22",
pages = "1465--1474",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11-12",

}

TY - JOUR

T1 - Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle

AU - Kalina, Warren V.

AU - Woolums, Amelia R.

AU - Berghaus, Roy D.

AU - Gershwin, Laurel J

PY - 2004/3/29

Y1 - 2004/3/29

N2 - Safe RSV vaccine development has challenged the medical community since a formalin-killed RSV vaccine caused disease exacerbation in the 1960s. Disease was replicated using the bovine RSV system in one of two studies. The studies differed in viral protein dose and length of time between vaccination and infection. Disease exacerbation occurred in study 2 (previously reported). We hypothesized that low protein concentration in study 2's vaccine stimulated a TH2/IgE response that enhanced disease. BRSV-specific IgG1, IgG2, and IgE were measured by ELISA/Western blot from vaccinated/infected, vaccinated/mock infected, mock vaccinated/infected calves in both studies. Results revealed that study 2 calves produced more IgE, particularly to the nucleoprotein (N); IgE among study 2 calves correlated with high clinical scores. In contrast, study 1 calves showed stronger IgG responses to viral proteins.

AB - Safe RSV vaccine development has challenged the medical community since a formalin-killed RSV vaccine caused disease exacerbation in the 1960s. Disease was replicated using the bovine RSV system in one of two studies. The studies differed in viral protein dose and length of time between vaccination and infection. Disease exacerbation occurred in study 2 (previously reported). We hypothesized that low protein concentration in study 2's vaccine stimulated a TH2/IgE response that enhanced disease. BRSV-specific IgG1, IgG2, and IgE were measured by ELISA/Western blot from vaccinated/infected, vaccinated/mock infected, mock vaccinated/infected calves in both studies. Results revealed that study 2 calves produced more IgE, particularly to the nucleoprotein (N); IgE among study 2 calves correlated with high clinical scores. In contrast, study 1 calves showed stronger IgG responses to viral proteins.

KW - Bovine

KW - Formalin-inactivated vaccine

KW - IgE

KW - RSV

UR - http://www.scopus.com/inward/record.url?scp=1842613514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842613514&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.10.024

DO - 10.1016/j.vaccine.2003.10.024

M3 - Article

C2 - 15063570

AN - SCOPUS:1842613514

VL - 22

SP - 1465

EP - 1474

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11-12

ER -